Skip to content
Medical Health Aged Care, Regional Country Services

Uniting supports choice in Voluntary Assisted Dying

Uniting NSW.ACT < 1 mins read

Media release                                                                             7 November 2025

Voluntary Assisted Dying (VAD) is an end-of-life option that terminally ill people in NSW may choose, provided they meet the eligibility criteria set out in the Act – it came into effect on 28 November 2023 across NSW.  This includes people who live in Residential Aged Care or who are receiving Home Care services in their own home.

Our focus at Uniting NSW.ACT has been and will continue to be to provide optimal symptom management, and psychosocial and spiritual support that palliative care provides to all people with a life limiting illness regardless of end of life choices. 

Uniting’s approach to VAD is to walk alongside our residents at end of life. We work to ensure if someone we care for with a life limiting illness wishes to explore VAD as an option, the individual, their family and their carers will not be made to feel judged, abandoned or scared that their care will be adversely affected.

Uniting recognises some staff members may wish to exercise their right to conscientious objection. Should staff decline to be involved in conversations about VAD, they can do so, and others will step in to assist the resident with referrals to progress their request.

Uniting’s Chief Executive Tracey Burton said, “We must remember residential aged care homes are exactly that - people’s homes - and older people have the same rights as those in the wider community. Uniting does not prevent our residents from seeking voluntary assisted dying if that is their wish.” 

Moderator of the Uniting Church Synod of NSW and ACT, Reverend Mata Havea Hiliau said the Church supports the personal views, theological beliefs and rights of all individuals regarding VAD.

Media contacts

Media & Public Affairs
Mobile: 
0457 568 938
Email: 
[email protected]

More from this category

  • Medical Health Aged Care
  • 04/03/2026
  • 08:56
Monash University

Monash University and Seaport Therapeutics Awarded up to $21 Million AUD from ARPA-H to Advance GlyphCeleTM, the First Oral Therapeutic Designed to Restore Gut Lymphatic Function

ARPA-H award supports the development of an oral prodrug, based on the Glyph™ platform initially developed at the Monash Institute of Pharmaceutical Sciences (MIPS), to address dysfunctional gut lymphatics linked to metabolic disease and pancreatic cancer. Monash University has announced the award of support from the Advanced Research Projects Agency for Health (ARPA-H) to advance an oral prodrug of celecoxib – using the GlyphTM platform and designed to deliver therapy directly to the gut lymphatics – aiming to improve lymphatic function and advance the treatment of metabolic disease and pancreatic cancer by directly addressing local inflammation and lymphatic dysfunction. The…

  • Medical Health Aged Care, Women
  • 04/03/2026
  • 06:00
Australia New Zealand Gynaecological Oncology Group (ANZGOG)

STRIVE clinical trial now available in Aotearoa New Zealand to improve outcomes in vulvar cancer

MEDIA RELEASE: Wednesday,4March2025 The Australian New Zealand Gynaecological Oncology Group (ANZGOG) in partnership with the Canadian Cancer Trials Group (CCTG) announces the local opening of theSTRIVEclinical trial– Stratification of Vulvar Squamous Cell Carcinoma by HPV and p53 status to Guide Excisionclinical trial (CCTG Protocol VU.2; ANZGOG Protocol ANZGOG2109/2021). STRIVErepresentsan important stepforward in advancing evidence-based surgical management for women diagnosed with vulvar squamous cell carcinoma (VSCC). About the STRIVE Trial STRIVE is an international, prospective, stratification study designed to refine surgical decision-making for patients withprimary vulvar squamous cell carcinoma(VSCC) based ontumourbiology. The study is led globally by the CCTG and led…

  • Medical Health Aged Care
  • 03/03/2026
  • 21:26
SAV-IOL

Lucidis® Sets High Standards in Premium Cataract Surgery with Full-Range Vision Performance

NEUCHÂTEL, Switzerland–BUSINESS WIRE– Swiss Advanced Vision announces new clinical evidence confirming the exceptional performance of its Lucidis® intraocular lens (IOL), strengthening its position as…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.